Superior Planning, LLC’s ADMA Biologics ADMA Stock Holding History

Superior Planning, LLC’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.07K	Buy	+107	New	+$990	﹤0.01%	1742

Other funds holding ADMA

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return

Life Cycle Investment Partners London $23.6B AUM 38.44% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Superior Planning, LLC's ADMA Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in ADMA Biologics (ADMA) in Q3 2026: 107 shares worth $1.07K. The stake represents ﹤0.01% of the portfolio and ranks #1742 among its holdings.

218 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

Superior Planning, LLC held 107 shares of ADMA Biologics worth $1.07K as of Q3 2026.
ADMA Biologics was a new Superior Planning, LLC position in Q3 2026.
ADMA Biologics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1742 holding.
218 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.